Pleiotropic roles in cancer biology for multifaceted proteins FKBPs

Biochimica et Biophysica Acta - General Subjects

Volumn 1850, Issue 10, 2015, Pages 2061-2068

  Romano, Simona ^a   D'Angelillo, Anna ^a   Romano, Maria Fiammetta ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cancer; FK506 binding protein; Peptidyl prolyl isomerase; Tumorigenesis

Indexed keywords

BIOLOGICAL MARKER; FK 506 BINDING PROTEIN; FK 506 BINDING PROTEIN 10; FK 506 BINDING PROTEIN 12; FK 506 BINDING PROTEIN 133; FK 506 BINDING PROTEIN 14; FK 506 BINDING PROTEIN 15; FK 506 BINDING PROTEIN 1A; FK 506 BINDING PROTEIN 2; FK 506 BINDING PROTEIN 24; FK 506 BINDING PROTEIN 25; FK 506 BINDING PROTEIN 3; FK 506 BINDING PROTEIN 36; FK 506 BINDING PROTEIN 37; FK 506 BINDING PROTEIN 38; FK 506 BINDING PROTEIN 4; FK 506 BINDING PROTEIN 5; FK 506 BINDING PROTEIN 51; FK 506 BINDING PROTEIN 52; FK 506 BINDING PROTEIN 54; FK 506 BINDING PROTEIN 59; FK 506 BINDING PROTEIN 6; FK 506 BINDING PROTEIN 65; FK 506 BINDING PROTEIN 8; ISOMERASE; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG; TUMOR MARKER; TUMOR PROTEIN;

ARTICLE; CANCER DIAGNOSIS; CANCER THERAPY; CARCINOGENESIS; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; IMMUNE DEFICIENCY; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; ANIMAL; GENETICS; METABOLISM;

ANIMALS; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION; TACROLIMUS BINDING PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84940581015     PISSN: 03044165     EISSN: 18728006     Source Type: Journal    
DOI: 10.1016/j.bbagen.2015.01.004     Document Type: Review

References (102)

1. M.A. Bjornsti, and P.J. Houghton The Tor pathway: a target for cancer therapy Nat. Canc. Rev. 4 2004 335 348 10.1038/nrc1362
2. M.S. Neshat, I.K. Mellinghoff, C. Tran, B. Stiles, G. Thomas, R. Petersen, P. Frost, J.J. Gibbons, H. Wu, and C.L. Sawyers Enhanched sensitivity of PTEN- deficient tumors to inhibition of FRAP/mTOR Proc. Natl. Acad. Sci. U. S. A. 98 2001 10314 10319 10.1073/pnas.171076798
3. B.T. Hennessy, D.L. Smith, P.T. Ram, Y. Lu, and G.B. Mills Exploiting the PI3K/AKT pathway for cancer drug discovery Nat. Rev. Drug Discov. 4 2005 988 1004 10.1038/nrd1902
4. S. Siamakpour-Reihani, D. Bandhu-Nepal, A. Courtwright, E. Hilliard, D. Ketelsen, C. Patterson, and N. Klauber-DeMore The calcineurin inhibitor tacrolimus inhibits breast tumor growth in vivo Cancer Res. 69 2009 10.1158/0008-5472.SABCS-09-3170 (Abstract nr 3170)
5. S. Jauliac, C. López-Rodriguez, L.M. Shaw, L.F. Brown, A. Rao, and A. Toker The role of NFAT transcription factors in integrin-mediated carcinoma invasion Nat. Cell Biol. 4 2002 540 544 10.1038/ncb816
6. M.R. Müller, and A. Rao Linking calcineurin activity to leukemogenesis Nat. Med. 13 2007 669 671 10.1038/nm0607-669
7. G. Hudes, M. Carducci, P. Tomczak, J. Dutcher, R. Figlin, A. Kapoor, E. Staroslawska, J. Sosman, D. McDermott, I. Bodrogi, Z. Kovacevic, V. Lesovoy, I.G. Schmidt-Wolf, O. Barbarash, E. Gokmen, T. O'Toole, S. Lustgarten, L. Moore, and R.J. Motzer Global ARCC trial, temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N. Engl. J. Med. 356 2007 2271 2281
8. S.N. Sehgal, H. Baker, and C. Vézina Rapamycin [AY-22,989], a new antifungal antibiotic. II, Fermentation, isolation and characterization J. Antibiot. 28 1975 727 732 10.7164/antibiotics.28.727
9. H. Tanaka, A. Kuroda, H. Marusawa, M. Hashimoto, H. Hatanaka, T. Kino, T. Goto, and M. Okuhara Physicochemical properties of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis Transplant. Proc. 19 1987 11 16
10. H. Yang, D.G. Rudge, J.D. Koos, B. Vaidialingam, H.J. Yang, and N.P. Pavletich mTOR kinase structure, mechanism and regulation Nature 497 2013 217 223 10.1038/nature12122
11. J. Dornan, P. Taylor, and M.D. Walkinshaw Structures of immunophilins and their ligand complexes Curr. Top. Med. Chem. 3 2003 1392 1409 10.2174/1568026033451899
12. J.A. Somarelli, S.Y. Lee, J. Skolnick, and R.J. Herrera Structure-based classification of 45 FK506-binding proteins Proteins 72 2008 197 208 10.1002/prot.21908
13. C.B. Kang, Y. Hong, S. Dhe-Paganon, and H.S. Yoon FKBP family proteins: immunophilins with versatile biological functions Neurosignals 16 2008 318 325 10.1159/000123041
14. G. Fischer, and T. Aumüller Regulation of peptide bond cis/trans isomerization by enzyme catalysis and its implication in physiological processes Rev. Physiol. Biochem. Pharmacol. 148 2003 105 150 10.1007/s10254-003-0011-3
15. M. Theuerkorn, G. Fischer, and C. Schiene-Fischer Prolyl cis/trans isomerase signalling pathways in cancer Curr. Opin. Pharmacol. 11 2011 281 287 10.1016/j.coph.2011.03.007
16. N.C. Guy, Y.A. Garcia, J.C. Sivils, M.D. Galigniana, and M.B. Cox Functions of the Hsp90-binding FKBP immunophilins Subcell. Biochem. 78 2015 35 68 10.1007/978-3-319-11731-7-2
17. D.L. Riggs, M.B. Cox, J. Cheung-Flynn, V. Prapapanich, P.E. Carrigan, and D.F. Smith Functional specificity of co-chaperone interactions with Hsp90 client proteins Crit. Rev. Biochem. Mol. Biol. 39 2004 279 295 10.1080/10409230490892513
18. S.P. Boudko, Y. Ishikawa, J. Nix, M.S. Chapman, and H.P. Bächinger Structure of human peptidyl-prolyl cis-trans isomerase FKBP22 containing two EF-hand motifs Protein Sci. 23 2014 67 75 10.1002/pro.2391
19. T.J. Pemberton, and J.E. Kay Identification and comparative analysis of the peptidyl-prolyl cis/trans isomerase repertoires of H. sapiens, D. melanogaster, C. elegans, S. cerevisiae and Sz. Pombe Comp. Funct. Genomics 6 2005 277 300 10.1002/cfg.482
20. M. Leclercq, F. Vinci, and A. Galat Mammalian FKBP-25 and its associated proteins Arch. Biochem. Biophys. 380 2000 20 28
21. Y. Wen-Ming, Y. Ya-Li, and S. Edward The FK506-binding protein 25 functionally associates with histone deacetylases and with transcription factor YY1 EMBO J. 20 2001 4814 4825 10.1093/emboj/20.17.4814
22. J.T. Zilfou, and M.E. Murphy Transcriptional Repression by the p53 Tumor Suppressor Protein G.P. Zambetti, The p53 Tumor Suppressor Pathway and Cancer. Springer e-book, series: Protein Reviews 2005 81 94
23. W.M. Yang, C.J. Inouye, and E. Seto Cyclophilin A and FKBP12 interact with YY1 and alter its transcriptional activity J. Biol. Chem. 270 1995 15187 15193
24. S. Romano, S. Staibano, A. Greco, A. Brunetti, G. Nappo, G. Ilardi, R. Martinelli, A. Sorrentino, A. Di Pace, M. Mascolo, R. Bisogni, M. Scalvenzi, B. Alfano, and M.F. Romano FK506 binding protein 51 positively regulates melanoma stemness and metastatic potential Cell Death Dis. 4 2013 e578 10.1038/cddis.2013.109
25. S. Romano, A. D'Angelillo, P. D'Arrigo, S. Staibano, A. Greco, A. Brunetti, M. Scalvenzi, R. Bisogni, I. Scala, and M.F. Romano FKBP51 increases the tumour-promoter potential of TGF-beta Clin. Transl. Med. 3 2014 1 10.1186/2001-1326-3-1
26. A.G. Erlejman, S.A. De Leo, G.I. Mazaira, A.M. Molinari, M.F. Camisay, V. Fontana, M.B. Cox, G. Piwien-Pilipuk, and M.D. Galigniana NF-κB transcriptional activity is modulated by FK506-binding proteins FKBP51 and FKBP52: a role for peptidyl-prolyl isomerase activity J. Biol. Chem. 289 2014 26263 26276 10.1074/jbc.M114.582882
27. C.L. Storer, C.A. Dickey, M.D. Galigniana, T. Rein, and M.B. Cox FKBP51 and FKBP52 in signaling and disease Trends Endocrinol. Metab. 22 2011 481 490 10.1016/j.tem.2011.08.001
28. Y. Ishikawa, and H.P. Bächinger A substrate preference for the rough endoplasmic reticulum resident protein FKBP22 during collagen biosynthesis J. Biol. Chem. 289 2014 18189 18201 10.1074/jbc.M114.561944
29. Y. Ishikawa, J. Vranka, J. Wirz, K. Nagata, and H.P. Bächinger The rough endoplasmic reticulum-resident FK506-binding protein FKBP65 is a molecular chaperone that interacts with collagens J. Biol. Chem. 283 2008 31584 31590 10.1074/jbc.M802535200
30. Y. Alanay, H. Avaygan, N. Camacho, G.E. Utine, K. Boduroglu, D. Aktas, M. Alikasifoglu, E. Tuncbilek, D. Orhan, F.T. Bakar, B. Zabel, A. Superti-Furga, L. Bruckner-Tuderman, C.J. Curry, S. Pyott, P.H. Byers, D.R. Eyre, D. Baldridge, B. Lee, A.E. Merrill, E.C. Davis, D.H. Cohn, N. Akarsu, and D. Krakow Mutations in the gene encoding the RER protein FKBP65 cause autosomal-recessive osteogenesis imperfecta Am. J. Hum. Genet. 86 2010 551 559
31. B. Zeng, J.R. MacDonald, J.G. Bann, K. Beck, J.E. Gambee, B.A. Boswell, and H.P. Bachinger Chicken FK506-binding protein, FKBP65, a member of the FKBP family of peptidylprolyl cis-trans isomerases, is only partially inhibited by FK506 Biochem. J. 330 1998 109 114
32. M.F. Romano FKBPs: opportunistic modifiers or active players in cancer? Curr. Opin. Pharmacol. 11 2011 279 280 10.1016/j.coph.2011.05.002
33. J.J. Siekierka, S.H. Hung, M. Poe, C.S. Lin, and N.H. Sigal A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin Nature 341 1989 755 757 10.1038/341755a0
34. S. Khatua, K.M. Peterson, K.M. Brown, C. Lawlor, M.R. Santi, B. LaFleur, D. Dressman, D.A. Stephan, and T.J. MacDonald Overexpression of the EGFR/FKBP12/HIF-2alpha pathway identified in childhood astrocytomas by angiogenesis gene profiling Cancer Res. 63 2003 1865 1870
35. S. Mathea, S. Li, A. Schierhorn, G. Jahreis, and C. Schiene-Fischer Suppression of EGFR autophosphorylation by FKBP12 Biochemistry 50 2011 10844 10850 10.1021/bi2013855
36. K.J. Hatanpaa, S. Burma, D. Zhao, and A.A. Habib Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance Neoplasia 12 2010 675 684
37. S. Romano, M. Mallardo, F. Chiurazzi, R. Bisogni, A. D'Angelillo, R. Liuzzi, G. Compare, and M.F. Romano The effect of FK506 on transforming growth factor beta signaling and apoptosis in chronic lymphocytic leukemia B cells Haematologica 93 2008 1039 1048 10.3324/haematol.12402
38. T. Wang, B.Y. Li, P.D. Danielson, P.C. Shah, S. Rockwell, R.J. Lechleider, J. Martin, T. Manganaro, and P.K. Donahoe The immunophilin FKBP12 functions as a common inhibitor of the TGF beta family type I receptors Cell 86 1996 435 444 10.1016/S0092-8674[00]80116-6
39. J.F. DeCoteau, P.I. Knaus, H. Yankelev, M.D. Reis, R. Lowsky, H.F. Lodish, and M.F. Kadin Loss of functional cell surface transforming growth factor beta [TGF-beta] type 1 receptor correlates with insensitivity to TGF-beta in chronic lymphocytic leukemia Proc. Natl. Acad. Sci. U. S. A. 94 1997 5877 5881
40. M. Baumann, C. Giunta, B. Krabichler, F. Rüschendorf, N. Zoppi, M. Colombi, R.E. Bittner, S. Quijano-Roy, F. Muntoni, S. Cirak, G. Schreiber, Y. Zou, Y. Hu, N.B. Romero, R.Y. Carlier, A. Amberger, A. Deutschmann, V. Straub, M. Rohrbach, B. Steinmann, K. Rostásy, D. Karall, C.G. Bönnemann, J. Zschocke, and C. Fauth Mutations in FKBP14 cause a variant of Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss Am. J. Hum. Genet. 90 2012 201 216 10.1016/j.ajhg.2011.12.004
41. M.E. Halatsch, S. Löw, T. Hielscher, U. Schmidt, A. Unterberg, and V.I. Vougioukas Epidermal growth factor receptor pathway gene expressions and biological response of glioblastoma multiforme cell lines to erlotinib Anticancer Res. 28 2008 3725 3728
42. W.M. Yang, Y.L. Yao, and E. Seto The FK506-binding protein 25 functionally associates with histone deacetylases and with transcription factor YY1 EMBO J. 20 2001 4814 4825
43. Y.L. Yao FKBPs in chromatin modification and cancer Curr. Opin. Pharmacol. 11 2011 301 307 10.1016/j.coph.2011.03.005
44. Y.J. Jin, and S.J. Burakoff The 25-kDa FK506-binding protein is localized in the nucleus and associates with casein kinase II and nucleolin Proc. Natl. Acad. Sci. U. S. A. 90 1993 7769 7773
45. T. Hideshima, R. Mazitschek, L. Santo, N. Mimura, G. Gorgun, P.G. Richardson, N. Raje, and K.C. Anderson Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitors Leukemia 28 2014 457 460 10.1038/leu.2013.301
46. K. Tsuboi, S. Iida, H. Inagaki, M. Kato, Y. Hayami, I. Hanamura, K. Miura, S. Harada, M. Kikuchi, H. Komatsu, S. Banno, A. Wakita, S. Nakamura, T. Eimoto, and R. Ueda MUM1/IRF4 expression as a frequent event in mature lymphoid malignancies Leukemia 14 2000 449 456
47. A.M. Ochocka, P. Kampanis, S. Nicol, N. Allende-Vega, M. Cox, L. Marcar, D. Milne, F. Fuller-Pace, and D. Meek FKBP25, a novel regulator of the p53 pathway, induces the degradation of MDM2 and activation of p53 FEBS Lett. 583 2009 621 626 10.1016/j.febslet.2009.01.009
48. J. Ahn, M. Murphy, S. Kratowicz, A. Wang, A.J. Levine, and D.L. George Down-regulation of the stathmin/Op18 and FKBP25 genes following p53 induction Oncogene 18 1999 5954 5958
49. P. Brebi, L. Maldonado, M.G. Noordhuis, C. Ili, P. Leal, P. Garcia, M. Brait, J. Ribas, C. Michailidi, J. Perez, E. Soudry, O. Tapia, P. Guzman, S. Muñoz, L. Van Neste, W. Van Criekinge, R. Irizarry, D. Sidransky, J.C. Roa, and R. Guerrero-Preston Genome-wide methylation profiling reveals Zinc finger protein 516 [ZNF516] and FK-506-binding protein 6 [FKBP6] promoters frequently methylated in cervical neoplasia, associated with HPV status and ethnicity in a Chilean population Epigenetics 9 2014 308 317 10.4161/epi.27120
50. T. Thomson, and H. Lin The biogenesis and function PIWI proteins and piRNAs: progress and prospect Annu. Rev. Cell Dev. Biol. 25 2009 355 376 10.1146/annurev.cellbio.24.110707.175327
51. M. Linnert, Y.J. Lin, A. Manns, K. Haupt, A.K. Paschke, G. Fischer, M. Weiwad, and C. Lücke The FKBP-type domain of the human aryl hydrocarbon receptor-interacting protein reveals an unusual Hsp90 interaction Biochemistry 52 2013 2097 2107 10.1021/bi301649m
52. J.R. Petrulis, N.G. Hord, and G.H. Perdew Subcellular localization of the aryl hydrocarbon receptor is modulated by the immunophilin homolog hepatitis B virus X-associated protein 2 J. Biol. Chem. 275 2000 37448 37453
53. N. Kuzhandaivelu, Y.S. Cong, C. Inouye, W.M. Yang, and E. Seto XAP2, a novel hepatitis B virus X-associated protein that inhibits X transactivation Nucleic Acids Res. 24 1996 4741 4750
54. Y.S. Cong, Y.L. Yao, W.M. Yang, N. Kuzhandaivelu, and E. Seto The hepatitis B virus X-associated protein, XAP3, is a protein kinase C-binding protein J. Biol. Chem. 272 1997 16482 16489
55. E. Tuominen, A. Heliövaara, M.R. Raitila, M. Rautiainen, R. Mehine, I. Katainen, V. Donner, H.J. Aittomäki, M. Lehtonen, L. Ahlsten, C. Kivipelto, J. Schalin-Jäntti, S. Arola, and A. Hautaniemi Karhu, AIP inactivation leads to pituitary tumorigenesis through defective Gαi-cAMP signaling Oncogene 2014 10.1038/onc.2014.50
56. R.M. Morgan Structure of the TPR domain of AIP: lack of client protein interaction with the C-terminal α-7 helix of the TPR domain of AIP is sufficient for pituitary adenoma predisposition PLoS ONE 7 2012 e53339 10.1371/journal.pone.0053339
57. Y. Zhou, X. Zhang, and A. Klibanski Genetic and epigenetic mutations of tumor suppressive genes in sporadic pituitary adenoma Mol. Cell. Endocrinol. 386 2014 16 33 10.1016/j.mce.2013.09.006
58. M. Vargiolu, D. Fusco, I. Kurelac, D. Dirnberger, R. Baumeister, I. Morra, A. Melcarne, R. Rimondini, G. Romeo, and E. Bonora The tyrosine kinase receptor RET interacts in vivo with aryl hydrocarbon receptor-interacting protein to alter survivin availability J. Clin. Endocrinol. Metab. 94 2009 2571 2578 10.1210/jc.2008-1980
59. E. Lam, M. Martin, and G. Wiederrecht Isolation of a cDNA encoding a novel human FK506-binding protein homolog containing leucine zipper and tetratricopeptide repeat motifs Gene 160 1995 297 302 10.1016/0378-1119[95]00216-S
60. F. Edlich, M. Weiwad, F. Erdmann, J. Fanghänel, F. Jarczowski, J.U. Rahfeld, and G. Fischer Bcl-2 regulator FKBP38 is activated by Ca2 +/calmodulin EMBO J. 24 2005 2688 2699 10.1038/sj.emboj.7600739
61. M. Shirane, and K.I. Nakayama Inherent calcineurin inhibitor FKBP38 targets Bcl-2 to mitochondria and inhibits apoptosis Nat. Cell Biol. 5 2003 28 37
62. K.M. Pedersen, B. Finsen, J.E. Celis, and N.A. Jensen muFKBP38: a novel murine immunophilin homolog differentially expressed in Schwannoma cells and central nervous system neurons in vivo Electrophoresis 20 1999 249 255
63. J. Wang, W. Tong, X. Zhang, L. Chen, Z. Yi, T. Pan, Y. Hu, L. Xiang, and Z. Yuan Hepatitis C virus non-structural protein NS5A interacts with FKBP38 and inhibits apoptosis in Huh7 hepatoma cells FEBS Lett. 580 2006 4392 4400 10.1016/j.febslet.2006.07.002
64. M.S. Choi, S.H. Min, H. Jung, J.D. Lee, T.H. Lee, H.K. Lee, and O.J. Yoo The essential role of FKBP38 in regulating phosphatase of regenerating liver 3 [PRL-3] protein stability Biochem. Biophys. Res. Commun. 406 2011 305 309 10.1016/j.bbrc.2011.02.037
65. S. Saha, A. Bardelli, P. Buckhaults, V.E. Velculescu, C. Rago, B. St Croix, K.E. Romans, M.A. Choti, C. Lengauer, K.W. Kinzler, and B. Vogelstein A phosphatase associated with metastasis of colorectal cancer Science 294 2001 1343 13461
66. X. Wu, H. Zeng, X. Zhang, Y. Zhao, H. Sha, X. Ge, M. Zhang, X. Gao, and Q. Xu Phosphatase of regenerating liver-3 promotes motility and metastasis of mouse melanoma cells Am. J. Pathol. 164 2004 2039 2054
67. S. Romano, A. Sorrentino, A.L. Di Pace, G. Nappo, C. Mercogliano, and M.F. Romano The emerging role of large immunophilin FK506 binding protein 51 in cancer Curr. Med. Chem. 18 2011 5424 5429 10.2174/092986711798194333
68. W. Jiang, S. Cazacu, C. Xiang, J.C. Zenklusen, H.A. Fine, M. Berens, B. Armstrong, C. Brodie, and T. Mikkelsen FK506 binding protein mediates glioma cell growth and sensitivity to rapamycin treatment by regulating NF-kappaB signaling pathway Neoplasia 10 2008 235 243
69. S. Periyasamy, T. Hinds Jr., L. Shemshedini, W. Shou, and E.R. Sanchez FKBP51 and Cyp40 are positive regulators of androgen-dependent prostate cancer cell growth and the targets of FK506 and cyclosporin A Oncogene 29 2010 1691 1701 10.1038/onc.2009.458
70. S. Staibano, M. Mascolo, G. Ilardi, M. Siano, and G. De Rosa Immunohistochemical analysis of FKBP51 in human cancers Curr. Opin. Pharmacol. 11 2011 338 347 10.1016/j.coph.2011.04.001
71. S. Romano, A. D'Angelillo, S. Staibano, G. Ilardi, and M.F. Romano FK506-binding protein 51 is a possible novel tumoral marker Cell Death Dis. 1 2010 e55 10.1038/cddis.2010.32
72. W.C. Yeh, T.K. Li, B.E. Bierer, and S.L. McKnight Identification and characterization of an immunophilin expressed during the clonal expansion phase of adipocyte differentiation Proc. Natl. Acad. Sci. U. S. A. 92 1995 11081 11085
73. S. Giraudier, H. Chagraoui, E. Komura, S. Barnache, B. Blanchet, J.P. LeCouedic, D.F. Smith, F. Larbret, A.L. Taksin, F. Moreau-Gachelin, N. Casadevall, M. Tulliez, A. Hulin, N. Debili, and W. Vainchenker Overexpression of FKBP51 in idiopathic myelofibrosis regulates the growth factor independence of megakaryocyte progenitors Blood 100 2002 2932 2940
74. L. Ni, C.S. Yang, D. Gioeli, H. Frierson, D.O. Toft, and B.M. Paschal FKBP51 promotes assembly of the Hsp90 chaperone complex and regulates androgen receptor signaling in prostate cancer cells Mol. Cell. Biol. 30 2010 1243 1253 10.1128/MCB. 01891-08
75. P.G. Febbo, M. Lowenberg, A.R. Thorner, M. Brown, M. Loda, and T.R. Golub Androgen mediated regulation and functional implications of FKBP51 expression in prostate cancer J. Urol. 173 2005 1772 1777
76. H. Makkonen, M. Kauhanen, V. Paakinaho, T. Jääskeläinen, and J.J. Palvimo Long-range activation of FKBP51 transcription by the androgen receptor via distal intronic enhancers Nucleic Acids Res. 37 2009 4135 4148 10.1093/nar/gkp352
77. A.M. Velasco, K.A. Gillis, Y. Li, E.L. Brown, T.M. Sadler, M. Achilleos, L.M. Greenberger, P. Frost, W. Bai, and Y. Zhang Identification and validation of novel androgen-regulated genes in prostate cancer Endocrinology 145 2004 3913 3924
78. R. Avellino, S. Romano, R. Parasole, R. Bisogni, A. Lamberti, V. Poggi, S. Venuta, and M.F. Romano Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells Blood, 106 2005 1400 1406
79. S. Romano, A. D'Angelillo, R. Pacelli, S. Staibano, E. De Luna, R. Bisogni, E.L. Eskelinen, M. Mascolo, G. Calì, C. Arra, and M.F. Romano Role of FK506 binding protein 51 [FKBP51] in the Control of Apoptosis of Irradiated Melanoma Cells Cell Death Differ. 17 2010 145 157 10.1038/cdd.2009.115
80. D.R. Daudt, and T. Yorio FKBP51 protects 661w cell culture from staurosporine-induced apoptosis Mol. Vis. 17 2011 1172 1181
81. M.F. Romano, R. Avellino, A. Petrella, R. Bisogni, S. Romano, and S. Venuta Rapamycin inhibits doxorubicin-induced NF-kappaB/Rel nuclear activity and enhances the apoptosis of melanoma cells Eur. J. Cancer 40 2004 2829 2836
82. L. Gallo, M. Lagadari, G. Piwien-Pilipuk, and M.D. Galigniana The 90-kDa heat-shock protein [Hsp90]-binding immunophilin FKBP51 is a mitochondrial protein that translocates to the nucleus to protect cells against oxidative stress J. Biol. Chem. 286 2011 30152 30160 10.1074/jbc.M111.256610
83. L. Bhushan, and R.P. Kandpal EphB6 receptor modulates micro RNA profile of breast carcinoma cells PLoS ONE 6 2011 e22484 10.1371/journal.pone.0022484
84. L. Wang FKBP51 regulation of AKT/protein kinase B phosphorylation Curr. Opin. Pharmacol. 11 2011 360 364 10.1016/j.coph.2011.03.008
85. A.K. Fabian, A. März, S. Neimanis, R.M. Biondi, C. Kozany, and F. Hausch InterAKTions with FKBPs-mutational and pharmacological exploration PLoS ONE 8 2013 e57508 10.1371/journal.pone.0057508
86. J.C. Sivils, C.L. Storer, M.D. Galigniana, and M.B. Cox Regulation of steroid hormone receptor function by the 52-kDa FK506-binding protein [FKBP52] Curr. Opin. Pharmacol. 11 2011 314 319 10.1016/j.coph.2011.03.010
87. B.K. Ward, P.J. Mark, D.M. Ingram, R.F. Minchin, and T. Ratajczak Expression of the estrogen receptor-associated immunophilins, cyclophilin 40 and FKBP52, in breast cancer Breast Cancer Res. Treat. 58 1999 267 280
88. G. Li, F. Zhao, and Y. Cui Proteomics using mammospheres as a model system to identify proteins deregulated in breast cancer stem cells Curr. Mol. Med. 13 2013 459 463
89. W.S. Yang, H.G. Moon, H.S. Kim, E.J. Choi, M.H. Yu, D.Y. Noh, and C. Lee Proteomic approach reveals FKBP4 and S100A9 as potential prediction markers of therapeutic response to neoadjuvant chemotherapy in patients with breast cancer J. Proteome Res. 11 2012 1078 1088 10.1021/pr2008187
90. J. Solassol, A. Mange, and T. Maudelonde FKBP family proteins as promising new biomarkers for cancer Curr. Opin. Pharmacol. 11 2011 320 325 10.1016/j.coph.2011.03.012
91. Y. Lui, C. Li, Z. Xing, X. Yuan, Y. Wu, M. Xu, K. Tu, Q. Li, C. Wu, M. Zhao, and R. Zeng Proteomic mining in the dysplastic liver of WHV/c-myc mice-insights and indicators for early hepatocarcinogenesis FEBS J. 277 2010 4039 4053 10.1111/j.1742-4658.2010.07795
92. C.E. Patterson, J. Gao, A.P. Rooney, and E.C. Davis Genomic organization of mouse and human 65 kDa FK506-binding protein genes and evolution of the FKBP multigene family Genomics 79 2002 881 889 10.1006/geno.2002.6777
93. R. Henriksen, F.B. Sørensen, T.F. ∅rntoft, and K. Birkenkamp-Demtroder Expression of FK506 binding protein 65 [FKBP65] is decreased in epithelial ovarian cancer cells compared to benign tumor cells and to ovarian epithelium Tumour Biol. 32 2011 671 676 10.1007/s13277-011-0167-4
94. M.C. Quinn, P.M. Wojnarowicz, A. Pickett, D.M. Provencher, A.M. Mes-Masson, E.C. Davis, and P.N. Tonin FKBP10/FKBP65 expression in high-grade ovarian serous carcinoma and its association with patient outcome Int. J. Oncol. 42 2013 912 920 10.3892/ijo.2013.1797
95. S.A. Tomlins, D.R. Rhodes, S. Perner, S.M. Dhanasekaran, R. Mehra, X.W. Sun, S. Varambally, X. Cao, J. Tchinda, R. Kuefer, C. Lee, J.E. Montie, R.B. Shah, K.J. Pienta, M.A. Rubin, and A.M. Chinnaiyan Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer Science 310 2005 644 648
96. S.H. Olesen, L.L. Christensen, F.B. Sørensen, T. Cabezón, S. Laurberg, T.F. Orntoft, and K. Birkenkamp-Demtröder Human FK506 binding protein 65 is associated with colorectal cancer Mol. Cell. Proteomics 4 2005 534 544
97. Y.F. Pan, I.M. Viklund, H.H. Tsai, S. Pettersson, and I.N. Maruyama The ulcerative colitis marker protein WAFL interacts with accessory proteins in endocytosis Int. J. Biol. Sci. 6 2010 163 171
98. O. Monstad, I.C. Hovde, and A.B. Solberg Moum, Clinical course and prognosis in ulcerative colitis: results from population-based and observational studies Ann. Gastroenterol. 27 2014 95 104
99. T. Robson, M.C. Joiner, G.D. Wilson, W. McCullough, M.E. Price, I. Logan, H. Jones, S.R. McKeown, and D.G. Hirst A novel human stress response-related gene with a potential role in induced radioresistance Radiat. Res. 152 1999 451 461
100. D.R. Bublik, M. Scolz, G. Triolo, M. Monte, and C. Schneider Human GTSE-1 regulates p21[CIP1/WAF1] stability conferring resistance to paclitaxel treatment J. Biol. Chem. 285 2010 5274 5281 10.1074/jbc.M109.045948
101. T. Robson, and I.F. James The therapeutic and diagnostic potential of FKBPL; a novel anticancer protein Drug Discov. Today 17 2012 544 548 10.1016/j.drudis.2012.01.002
102. H.D. McKeen, C. Byrne, P.V. Jithesh, C. Donley, A. Valentine, A. Yakkundi, M. O'Rourke, C. Swanton, H.O. McCarthy, D.G. Hirst, and T. Robson FKBPL regulates estrogen receptor signaling and determines response to endocrine therapy Cancer Res. 70 2010 1090 1100 10.1158/0008-5472.CAN-09-2515